The Utility of FDG-PET for Radiation Treatment in NSCLC

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by AHS Cancer Control Alberta.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Calgary Health Region
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00385164
First received: October 4, 2006
Last updated: January 18, 2012
Last verified: August 2011
  Purpose

Patients planned for radical radiation for NSCLC will undergo conventional CT stimulation and also PET/CT scans for definition of radiation target volumes


Condition Intervention Phase
Lung Neoplasms
Positron Emission Tomography
Procedure: PET/CT scan for RT planning
Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Estimated Enrollment: 50
Study Start Date: October 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Non-small cell lung cancer

Criteria

Inclusion Criteria:

  • Non-small cell lung cancer to receive radical radiation

Exclusion Criteria:

  • unable to tolerate PET/CT scan
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00385164

Contacts
Contact: Harold P Lau, MD 403-521-3012

Locations
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Marilyn David    403-521-3619    marilyn.david@albertahealthservices.ca   
Sponsors and Collaborators
AHS Cancer Control Alberta
Calgary Health Region
Investigators
Principal Investigator: Harold P Lau, MD AHS Cancer Control Alberta
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00385164     History of Changes
Other Study ID Numbers: 20328, E-20328
Study First Received: October 4, 2006
Last Updated: January 18, 2012
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
lung neoplasms
positron emissions tomography
radiotherapy planning

Additional relevant MeSH terms:
Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 26, 2014